176 related articles for article (PubMed ID: 12880373)
1. Interleukin-10-based therapy for inflammatory bowel disease.
Braat H; Peppelenbosch MP; Hommes DW
Expert Opin Biol Ther; 2003 Aug; 3(5):725-31. PubMed ID: 12880373
[TBL] [Abstract][Full Text] [Related]
2. IL-10 and its related cytokines for treatment of inflammatory bowel disease.
Li MC; He SH
World J Gastroenterol; 2004 Mar; 10(5):620-5. PubMed ID: 14991925
[TBL] [Abstract][Full Text] [Related]
3. Actobiotics as a novel method for cytokine delivery.
Steidler L; Rottiers P; Coulie B
Ann N Y Acad Sci; 2009 Dec; 1182():135-45. PubMed ID: 20074282
[TBL] [Abstract][Full Text] [Related]
4. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
5. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.
Duchmann R; Schmitt E; Knolle P; Meyer zum Büschenfelde KH; Neurath M
Eur J Immunol; 1996 Apr; 26(4):934-8. PubMed ID: 8625991
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
7. Alterations of the mucosal immune system in inflammatory bowel disease.
MacDermott RP
J Gastroenterol; 1996 Dec; 31(6):907-16. PubMed ID: 9027661
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-27 as a Novel Therapy for Inflammatory Bowel Disease: A Critical Review of the Literature.
Andrews C; McLean MH; Durum SK
Inflamm Bowel Dis; 2016 Sep; 22(9):2255-64. PubMed ID: 27243591
[TBL] [Abstract][Full Text] [Related]
9. Novel cytokine-targeted therapies and intestinal inflammation.
Waldner MJ; Neurath MF
Curr Opin Pharmacol; 2009 Dec; 9(6):702-7. PubMed ID: 19674937
[TBL] [Abstract][Full Text] [Related]
10. Why interleukin-10 supplementation does not work in Crohn's disease patients.
Marlow GJ; van Gent D; Ferguson LR
World J Gastroenterol; 2013 Jul; 19(25):3931-41. PubMed ID: 23840137
[TBL] [Abstract][Full Text] [Related]
11. New therapies for inflammatory bowel disease: an update on chimeric anti-TNF alpha antibodies and IL-10 therapy.
van Hogezand RA; Verspaget HW
Scand J Gastroenterol Suppl; 1997; 223():105-7. PubMed ID: 9200315
[TBL] [Abstract][Full Text] [Related]
12. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe?
Reuter BK; Pizarro TT
Eur J Immunol; 2004 Sep; 34(9):2347-55. PubMed ID: 15307167
[TBL] [Abstract][Full Text] [Related]
13. Germ therapy with IL-10 to treat inflammatory bowel diseases.
Michie C
Mol Med Today; 2000 Nov; 6(11):416. PubMed ID: 11074364
[No Abstract] [Full Text] [Related]
14. Cytokines in inflammatory bowel disease.
Kmieć Z
Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
[TBL] [Abstract][Full Text] [Related]
15. Role of interleukin-22 in inflammatory bowel disease.
Li LJ; Gong C; Zhao MH; Feng BS
World J Gastroenterol; 2014 Dec; 20(48):18177-88. PubMed ID: 25561785
[TBL] [Abstract][Full Text] [Related]
16. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
17. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics.
Linskens RK; Huijsdens XW; Savelkoul PH; Vandenbroucke-Grauls CM; Meuwissen SG
Scand J Gastroenterol Suppl; 2001; (234):29-40. PubMed ID: 11768558
[TBL] [Abstract][Full Text] [Related]
18. Immunology. Therapeutic manipulation of gut flora.
Shanahan F
Science; 2000 Aug; 289(5483):1311-2. PubMed ID: 10979858
[TBL] [Abstract][Full Text] [Related]
19. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
Simčič S; Berlec A; Stopinšek S; Štrukelj B; Orel R
World J Microbiol Biotechnol; 2019 Feb; 35(3):45. PubMed ID: 30810891
[TBL] [Abstract][Full Text] [Related]
20. A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease.
Vossenkämper A; Hundsrucker C; Page K; van Maurik A; Sanders TJ; Stagg AJ; Das L; MacDonald TT
Gastroenterology; 2014 Jul; 147(1):172-83. PubMed ID: 24704524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
